ALX Oncology Holdings Inc
ALXO
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
ALX Oncology develops immuno-oncology therapies targeting CD47, a 'don't eat me' signal exploited by cancer cells. Its lead candidate evorpacept blocks CD47 with high affinity and is being evaluated in Phase 2 trials for HER2-positive breast cancer combined with trastuzumab. The company also has ALX2004, a novel EGFR-targeted antibody-drug conjugate in Phase 1 dose escalation. Preclinical development relied heavily on animal models: evorpacept demonstrated enhanced tumor clearance and macrophage activation in solid tumor and hematologic xenograft models, and non-human primate toxicology studies confirmed a favorable safety profile at clinically relevant doses. ALX Oncology continues to present preclinical data at AACR, with new animal model results on firmonertinib and ARR-002 scheduled for the 2026 meeting.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.